Home, home below the range: all five deals this week priced below the range. There were eleven companies on the IPO calendar this week, but only five were able to price, and each of those priced at least 19% below their proposed...read more
Edge Therapeutics, which is developing a sustained-release therapy for limiting brain injury after aneurysms, raised $80 million by offering 7.3 million shares at $11, far below the range of $14 to $16. Edge Therapeutics plans to list on the Nasdaq under the...read more
The last week of September has 11 IPOs on the calendar – more IPOs than all of August 2015.
Out of 134 offerings so far in 2015, 61 have been health care companies. Next week, 7 out of the 11 IPOs on the calendar are health care. ...read more
Edge Therapeutics, which is developing a sustained-release therapy for ruptured brain aneurysms, announced terms for its IPO on Monday.
The Berkeley Heights, NJ-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14 ...read more
US IPO Weekly Recap: Only five deals get done after massive valuation cuts
Home, home below the range: all five deals this week priced below the range. There were eleven companies on the IPO calendar this week, but only five were able to price, and each of those priced at least 19% below their proposed...read more
Edge Therapeutics prices IPO at $11, far below the range
Edge Therapeutics, which is developing a sustained-release therapy for limiting brain injury after aneurysms, raised $80 million by offering 7.3 million shares at $11, far below the range of $14 to $16. Edge Therapeutics plans to list on the Nasdaq under the...read more
Week ahead: 11 IPOs set to price during the week of September 28
The last week of September has 11 IPOs on the calendar – more IPOs than all of August 2015. Out of 134 offerings so far in 2015, 61 have been health care companies. Next week, 7 out of the 11 IPOs on the calendar are health care. ...read more
A cutting edge biotech: Edge Therapeutics sets terms for $85 million IPO
Edge Therapeutics, which is developing a sustained-release therapy for ruptured brain aneurysms, announced terms for its IPO on Monday. The Berkeley Heights, NJ-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14 ...read more